Evista
NDC Package 0002-4165-07

The code 0002-4165-07 identifies a specific commercial package of 1 bottle in 1 carton / 2000 tablet in 1 bottle of Evista, labeled by Eli Lilly And Company. This is formulated for use and contains as the active substance.

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Eli Lilly And Company on January 06, 1998. The current certification is valid through July 09, 2018.

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break. Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause. Raloxifene is not an estrogen hormone, but it acts like estrogen in some parts of the body, like your bones. In other parts of the body (uterus and breasts), raloxifene acts like an estrogen blocker. It does not relieve menopause symptoms such as hot flashes. Raloxifene belongs to a class of drugs known as selective estrogen receptor modulators-SERMs. This medication should not be used before menopause. It should not be used to prevent heart disease.

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00002416507. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 1 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.